© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Pazufloxacin Mesylate stands out as a fluoroquinolone antibiotic, chemically designed to target a wide range of bacterial infections. In clinical practice, it supports professionals in fighting pathogens resistant to common treatments, making it a valuable tool in the infectious diseases arsenal. This compound, recognized by its international standards and regulatory listings, provides options to both hospitals and research institutions faced with persistent or hospital-acquired infections.
In appearance, Pazufloxacin Mesylate frequently comes as a white to pale yellow crystalline powder, though batches can show minor variations from this norm, thanks to elemental impurities or differences in synthesis. Solubility emerges as one of its central characteristics; dissolving well in water, it allows for intravenous and oral solutions, contributing to patient flexibility and dosing control. As a raw material, density sits near the 1.5 g/cm³ mark, compact enough for formulation but not so fine as to cause uncontrolled dusting during handling. Firms shipping bulk often provide flaked, granular, or powdered forms, matching downstream processing equipment. Notable is the absence of odor and a relatively stable structure under ambient conditions, though manufacturers recommend sealed storage away from heat and light to keep the substance potent and safe.
From a chemical view, Pazufloxacin Mesylate holds a complex quinolone skeleton. Its molecular formula, C15H12FN3O3·CH4O3S, lists the mesylate group as part of the compound's stability and solubility package. The structure features fused rings and a fluorine substituent that increases antibacterial strength. Each batch pairs with certificate of analysis documentation, ensuring users know the molecular purity and impurity profile, an important point under international guidelines for pharmaceutical ingredients.
Respected suppliers deliver Pazufloxacin Mesylate under tightly controlled specifications. Particle size matters, as over-sized grains affect solution clarity and injectability, whereas too-fine powders complicate handling. Standard lots arrive with certification of content, usually exceeding 98% by HPLC, with loss on drying and residue on ignition all carefully measured. Each drum or interior pouch carries a hazard label, complying with global GHS standards—protective measures match its profile as a chemical active, not a benign consumable. Packaging handles both solid crystal and powder textures, capped for moisture resistance and easy transfer to compounding rooms. For chemists, knowing the melting point—often listed around 270°C—ensures identity and quality, guarding against substitution.
On the logistics side, Pazufloxacin Mesylate ships under the HS Code 2934.99, which covers various antibiotics with complex heterocyclic structures. This classification matters for customs declarations and sets the pace for regulatory compliance, influencing how shipments cross borders and which import documents local authorities demand. Shippers attach safety data sheets that flag concerns such as irritation risks to the skin and eyes. Handling guidelines urge gloves, goggles, and dust control, both for direct users and warehouse staff. Both large shipments—often in 25 kg fiber drums—and research-scale vials use the same labeling, helping teams track and trace through distribution networks.
As a chemical raw material, Pazufloxacin Mesylate arrives with several safety imperatives. Laboratory workers lean on experience and established company SOPs, wearing N95 masks during powder weighing and using exhaust hoods for solution preparation. Direct skin or eye contact may irritate, and inhalation could produce measurable respiratory effects in sensitive individuals, so risk management involves more than just paperwork; it calls for well-designed engineering controls and vigilant personal habits. Waste handling professionals segregate unused activator from regular trash, classifying it as hazardous chemical waste. During shipping, insulated and cushioned containers prevent breakage or accidental spillage, supporting health and environmental standards.
Beyond the laboratory, Pazufloxacin Mesylate drives progress in acute care hospitals, especially with its role in the treatment of pneumonia, complicated urinary tract infections, and some forms of sepsis. It interfaces with the pharmacy supply chain, requiring rigorous quality management from receipt through compounding and administration. In the research realm, laboratory teams turn to this molecule for resistant strain profiling, supporting both basic science and drug development pipelines. Sometimes regulatory filings require even deeper analysis, compelling manufacturers to document every aspect from raw material sourcing to impurity limits. Institutions using Pazufloxacin Mesylate remain subject to inspection by health authorities, who look for evidence of secure storage, trained staff, and clear audit trails.
Responsible management means safeguarding both the immediate workforce and the environment. Pazufloxacin Mesylate requires dry, cool storage conditions, with many facilities holding stocks at under 25°C to block any chance of degradation. Firms with experience in chemical storage use desiccant packs, controlled humidity rooms, and periodic shelf-life checks to avoid wasting expensive and valuable product. Wastewater streams from cleaning or accidental spills pass through dedicated treatment steps; antibiotics exiting into municipal water supplies raise well-known concerns over resistance, so facilities bear a duty to apply activated carbon filtration or chemical neutralization methods before discharge. Sustainability circles call for even closer tracking and documentation of usage rates to match demand and minimize leftovers.
